Medicare Enrolled
Dr. Servillano Dela Cruz, M.D.
Medical Oncology · Inverness, FL
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Dela Cruz from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Dela Cruz? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Dela Cruz
Dr. Servillano Dela Cruz is a medical oncology in Inverness, FL, with 20 years in practice. Based on federal Medicare data, Dr. Dela Cruz performed 144,341 Medicare services across 3,130 unique beneficiaries.
Between the years covered by Open Payments, Dr. Dela Cruz received a total of $80,697 from 96 pharmaceutical and/or device companies across 1197 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Dela Cruz is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice▲ Top 18% volume in FL$ $80,697 industry payments
Medicare Practice Summary
Medicare Utilization ↗144,341
Medicare services
Top 18% in FL for medical oncology
3,130
Unique beneficiaries
$5
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~7,217 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron infusion (Feraheme) | 99,960 | $0 | $4 |
| Epoetin alfa injection (Procrit) for anemia | 10,760 | $6 | $23 |
| Denosumab injection (Prolia/Xgeva) | 9,600 | $18 | $51 |
| Anti-nausea injection (aprepitant) | 8,970 | $1 | $5 |
| Immune globulin infusion (Gammagard) | 5,052 | $36 | $108 |
| Blood draw (venipuncture) | 1,861 | $8 | $9 |
| Complete blood count (CBC) with differential | 1,858 | $8 | $29 |
| Dexamethasone injection (steroid) | 972 | $0 | $3 |
| Drug injection, under skin or into muscle | 827 | $10 | $69 |
| Anti-nausea injection (Aloxi/palonosetron) | 700 | $1 | $28 |
| Office visit, established patient (30-39 min) | 539 | $95 | $339 |
| Office visit, established patient (20-29 min) | 519 | $62 | $239 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 290 | $1 | $6 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 287 | $46 | $189 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 287 | $22 | $84 |
| Injection of additional new drug or substance into vein | 258 | $12 | $61 |
| Administration of chemotherapy into vein, 1 hour or less | 234 | $96 | $378 |
| Red blood count, automated test | 228 | $4 | $10 |
| Injection, diphenhydramine hcl, up to 50 mg | 179 | $1 | $3 |
| Infusion into a vein for therapy, prevention, or diagnosis, each additional hour | 158 | $15 | $56 |
| Injection, zoledronic acid, 1 mg | 139 | $6 | $69 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 86 | $17 | $59 |
| Injection of drug or substance into vein | 85 | $28 | $156 |
| Administration of chemotherapy into vein, each additional hour | 82 | $21 | $79 |
| Office visit, established patient, complex (40-54 min) | 60 | $137 | $474 |
| New patient office visit (30-44 min) | 51 | $79 | $298 |
| Prothrombin time test (blood clotting) | 47 | $4 | $15 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 42 | $25 | $89 |
| Injection, methylprednisolone sodium succinate, up to 40 mg | 42 | $3 | $11 |
| Administration of additional new drug or substance into vein, 1 hour or less | 34 | $49 | $178 |
| Drawing of blood for a medical problem | 22 | $50 | $277 |
| Initial hospital admission, high complexity | 22 | $137 | $556 |
| Hospital follow-up visit, moderate complexity | 22 | $63 | $197 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 19 | $1 | $7 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 17 | $134 | $467 |
| Infusion into a vein for hydration, 31-60 minutes | 16 | $22 | $156 |
| New patient office visit (45-59 min) | 16 | $131 | $453 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
73.3% high complexity
23.0% medium
3.7% routine
Industry Payment Transparency
Open Payments through 2024 ↗$80,697
Total received (2018-2024)
Avg $11,528/year across 7 years
Top 9% in FL for medical oncology
96
Companies
1,197
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$48,785 (60.5%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$21,652 (26.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$10,260 (12.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$29,126
2023$6,630
2022$8,628
2021$10,336
2020$8,808
2019$13,449
2018$3,720
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
EMD Serono, Inc.
$20,886
Novartis Pharmaceuticals Corporation
$8,935
Astellas Pharma US Inc
$7,682
AstraZeneca Pharmaceuticals LP
$5,751
Janssen Biotech, Inc.
$4,200
GENZYME CORPORATION
$2,718
Verastem, Inc.
$2,689
Karyopharm Therapeutics Inc.
$2,347
E.R. Squibb & Sons, L.L.C.
$2,188
Pharmacosmos Therapeutics Inc.
$1,543
Taiho Oncology, Inc.
$1,478
Incyte Corporation
$1,383
Celgene Corporation
$1,371
ARRAY BIOPHARMA INC
$1,318
Epizyme, Inc.,
$1,262
PFIZER INC.
$962
Amgen Inc.
$961
Daiichi Sankyo Inc.
$787
BeiGene USA, Inc.
$756
Lilly USA, LLC
$731
Merck Sharp & Dohme Corporation
$691
Seagen Inc.
$619
GlaxoSmithKline, LLC.
$602
Pharmacyclics LLC, An AbbVie Company
$563
Bayer HealthCare Pharmaceuticals Inc.
$472
Takeda Pharmaceuticals U.S.A., Inc.
$403
Eisai Inc.
$403
Kite Pharma, Inc.
$389
Seattle Genetics, Inc.
$350
EISAI INC.
$317
Gilead Sciences, Inc.
$310
AMAG Pharmaceuticals, Inc.
$302
Regeneron Healthcare Solutions, Inc.
$301
Merck Sharp & Dohme LLC
$298
Boehringer Ingelheim Pharmaceuticals, Inc.
$277
Genentech USA, Inc.
$275
TESARO, Inc.
$227
PUMA BIOTECHNOLOGY, INC.
$203
Lexicon Pharmaceuticals, Inc.
$197
JAZZ PHARMACEUTICALS INC.
$195
Clovis Oncology, Inc.
$174
Pharmacyclics LLC, an AbbVie Company
$166
G1 Therapeutics, Inc.
$156
Alexion Pharmaceuticals, Inc.
$150
Octapharma USA, Inc.
$144
Foundation Medicine, Inc.
$144
SOBI, INC
$126
Blueprint Medicines Corporation
$125
Mirati Therapeutics, Inc.
$118
Bayer Healthcare Pharmaceuticals Inc.
$106
Puma Biotechnology, Inc.
$92
Heron Therapeutics, Inc.
$91
ADC Therapeutics America, Inc.
$90
PharmaEssentia USA Corporation
$87
Agios Pharmaceuticals, Inc.
$81
TAIHO ONCOLOGY, INC.
$78
SERVIER PHARMACEUTICALS LLC
$77
Janssen Scientific Affairs, LLC
$71
ABBVIE INC.
$69
Exelixis Inc.
$69
AVEO Pharmaceuticals, Inc.
$61
Dova Pharmaceuticals
$60
AbbVie, Inc.
$57
CTI BioPharma Corp.
$57
Array BioPharma Inc.
$55
Sobi, Inc
$52
Rigel Pharmaceuticals, Inc.
$50
Ipsen Biopharmaceuticals, Inc
$48
Spectrum Pharmaceuticals Inc.
$46
CSL Behring
$42
Sysmex Inostics Inc
$41
MEDIVATION FIELD SOLUTIONS LLC
$40
MorphoSys, US Inc.
$38
Secura Bio, Inc.
$36
Alnylam Pharmaceuticals Inc.
$34
AbbVie Inc.
$32
Partner Therapeutics, Inc.
$32
Genmab U.S., Inc.
$30
Kyowa Kirin, Inc.
$27
Myriad Genetic Laboratories, Inc.
$25
Sun Pharmaceutical Industries Inc.
$24
Stemline Therapeutics Inc.
$23
EUSA Pharma (US) LLC
$23
TerSera Therapeutics LLC
$21
Deciphera Pharmaceuticals Inc.
$20
Jazz Pharmaceuticals Inc.
$18
Novo Nordisk Inc
$18
INSYS Therapeutics Inc
$18
GE HealthCare
$17
Acrotech Biopharma LLC
$17
TG THERAPEUTICS, INC.
$16
Tempus AI, Inc
$16
Emmaus Medical, Inc.
$15
Immunomedics, Inc.
$14
Aurobindo Pharma USA, Inc.
$13
GE HEALTHCARE
$12
Top 3 companies account for 46.5% of total payments
Associated products mentioned in payments ›
ADAKVEO · ADCETRIS · ALIMTA · ALUNBRIG · AYVAKIT · Abraxane · Afstyla · Alecensa · Aliqopa · BAVENCIO · BELEODAQ · BESREMI · BLENREP · BOSULIF · BRACANALYSIS CDX · BRAFTOVI · BRUKINSA · Balversa · Bavencio · Braftovi · CABLIVI · CABOMETYX · CALQUENCE · CARVYKTI · CEREZYME · CINVANTI · COSELA · CUTAQUIG · CYRAMZA · Cabometyx · Cinvanti · Copiktra · DARZALEX · DOPTELET · Doptelet · ELITEK · ENHERTU · ERBITUX · ERLEADA · EVENITY · EXKIVITY · Endari · Enhertu · Epkinly · Erleada · FARYDAK · FERAHEME · FOTIVDA · FOUNDATIONONE · FRUZAQLA · Fabhalta · Farydak · Folotyn · GAUCHER-DISEASE · GAVRETO · GAZYVA · GILOTRIF · GIVLAARI · GLYXAMBI · Halaven · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · INREBIC · Idelvion · Imbruvica · Inrebic · JAKAFI · JEMPERLI · JEVTANA · Jivi · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LOKELMA · LONSURF · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Leukine · Lonsurf · MEKINIST · MONJUVI · MONOFERRIC · MVASI · MYLOTARG · Monoferric · NERLYNX · NINLARO · Neulasta · Nexavar · Nplate · Nubeqa · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ODOMZO · OJJAARA · ONUREG · OPDIVO · OPDUALAG · Orserdu · Ozempic · PADCEV · PIQRAY · PLUVICTO · PROMACTA · PROSTATE CANCER - DISEASE · Padcev · Perjeta · Phesgo · Pomalyst · Poteligeo · Prolia · QINLOCK · REBLOZYL · ROLVEDON · RYBREVANT · RYDAPT · Revlimid · Rezlidhia · Rubraca · SANDOSTATIN · SARCLISA · SCEMBLIX · SHINGRIX · SOLIRIS · SOMATULINE DEPOT · SUSTOL · SUTENT · SYNDROS · Somatuline Depot · Stivarga · Sylvant · TABRECTA · TAFINLAR · TAGRISSO · TASIGNA · TAXOTERE · TAZVERIK · TECENTRIQ · TECVAYLI · TIBSOVO · TUKYSA · Tavalisse · Tibsovo · Trodelvy · UKONIQ · ULTOMIRIS · Ultomiris · VENCLEXTA · VERZENIO · VONJO · VOTRIENT · VYNDAMAX · Venclexta · Vitrakvi · Vonjo · XALKORI · XGEVA · XOSPATA · XPOVIO · XT CDX · XTANDI · Xermelo · Xofigo · Xospata · Xtandi · Yescarta · ZEJULA · ZEPZELCA · ZOLADEX
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (60%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers. Total industry engagement is in the top 9% for medical oncology in FL.
Equivalent to $56 per 100 Medicare services performed
Geographic Context
Medical Oncologys within 10 mi
7
Per 100K population
4.4
County median income
$55,355
Nearest hospital
HCA FLORIDA CITRUS HOSPITAL
9.7 mi
9.7 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Dela Cruz is a mixed practice specialist, with above-average Medicare volume (top 18% in FL), and high industry engagement (consulting-driven, top 9%), with 20 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Dela Cruz experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Dela Cruz performed 99,960 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Dela Cruz receive payments from pharmaceutical companies?
Yes. Dr. Dela Cruz received a total of $80,697 from 96 companies across 1,197 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Dela Cruz's costs compare to other medical oncologys in Inverness?
Dr. Dela Cruz's average Medicare payment per service is $5. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Dela Cruz) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Medical Oncologys in Inverness
Browse medical oncologys in Inverness ranked by procedure volume and transparency data.
Highest volume
Top Medical Oncologys in FL
Medical Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Medical Oncologys in FL
Which FL medical oncologys receive the most from drug and device companies.
By company
EMD Serono, Inc. Payments to Doctors
See all physicians who received payments from EMD Serono, Inc..
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
Astellas Pharma US Inc Payments to Doctors
See all physicians who received payments from Astellas Pharma US Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology